According to the latest report by IMARC Group, titled “Generic Drug Market: Japan Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the Japan generic drug market size reached US$ 10.7 Billion in 2022. Generic drugs refer to pharmaceutical products that are bioequivalent to brand-name drugs in terms of strength, dosage form, route of administration, safety, efficacy, and quality. They are developed and marketed after the patent protection of the original brand-name drug expires. Generic drugs provide an affordable alternative to their brand-name counterparts, offering the same therapeutic benefits at a lower cost. In order to produce a generic drug, manufacturers demonstrate that it contains the same active ingredient(s) as the brand-name drug and meets strict quality standards set by regulatory authorities. The manufacturing facilities and processes for generic drugs must adhere to Good Manufacturing Practices (GMP) to ensure consistency, safety, and effectiveness. Generic drugs undergo a rigorous approval process, including comprehensive testing and evaluation to establish their bioequivalence to the brand-name drug, which means that they are absorbed and distributed in the body at similar rates, thus leading to comparable therapeutic outcomes. Moreover, generic drugs enhance market competition, which can drive down prices and improve overall healthcare affordability.
Japan Generic Drug Market Trends:
The increasing demand for affordable medicines represents one of the key factors driving the growth of the market across Japan. In addition to this, healthcare providers and consumers becoming more familiar with their benefits due to the increasing availability of more generic drug options is leading to higher adoption rates, thereby contributing to the market growth. The market is also driven by the Government of Japan actively promoting the use of generic drugs to control healthcare costs. The implementation of policies and initiatives to encourage the prescribing and consumption of generic drugs is acting as a major growth-inducing factor. This includes measures, such as pricing regulations, incentives for physicians, and public awareness campaigns, which are fueling the growth of the market. In line with this, the increasing demand for pharmaceutical products, along with the steadily expanding geriatric population base is driving the demand for generic drugs, which is contributing to the growth of the market. The increasing preference for generic drugs that offer cost-effective alternatives to brand-name drugs due to their affordability is propelling the market growth. In addition to this, the rising healthcare expenditures, along with the increasing demand for cost-effective solutions to manage healthcare costs without compromising the quality of healthcare services are facilitating the growth of the market across the country. Looking forward, the market value is projected to reach US$ 16.9 Billion by 2028, expanding at a CAGR of 7.8% during 2023-2028.
- The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the key players operating in the industry.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800